ＸＥＬＯＸ方案治疗进展期胃癌的临床观察

目的　探讨奥沙利铂联合卡培他滨（ＸＥＬＯＸ）方案一线治疗进展期胃癌的疗效和不良反应。方法　回顾性分析７１例经病理组织学检查证实的胃癌患者，给予ＸＥＬＯＸ方案化疗，具体为：奥沙利铂１３０ｍｇ／ｍ^２静滴，第１天；卡培他滨１０００ｍｇ／ｍ^２口服，２次／日，第１～１４天，２１天为１周期。记录治疗的有效率（ＲＲ）、疾病进展时间（ＴＴＰ）、总生存时间（ＯＳ）和不良反应。结果　７１例患者共完成３２０个周期化疗，ＲＲ为４３７％（９５％ＣＩ：３６.３％ ～６２.９％），包括ＣＲ５例（７.０％），ＰＲ２６例（３６.６％），中位ＴＴＰ为７.５个月（９５％ＣＩ：６.４～８.５个月），中位ＯＳ为１１个月（９５％ＣＩ：８.２～１３.８个月）。主要不良反应以１～２级为主，３级不良反应包括恶心呕吐４例、腹泻５例、外周感觉神经症状５例、手足综合征７例和中性粒细胞缺乏６例，无化疗相关性死亡。结论　ＸＥＬＯＸ方案一线治疗进展期胃癌疗效较好，毒副反应可以耐受，使用方便，值得临床进一步研究。

Oxaliplatin and capecitabine regimen for patients with advanced gastric cancer

Objective To explore oxaliplatin in combination with capecitabine(XELOX regimen) as first-line chemotherapy in advanced gastric cancer(AGC).Methods Seventy-one patients with histologically confirmed gastric cancer were retrospectively analyzed.All of the patients were prescribed oxaliplatin 130 mg/m2 intravenously on day 1 and capecitabine 1000 mg/m2 orally twice a day,on days 1-14.Twenty-one days was a cycle.The primary endpoint was response rate(RR),and the secondary endpoint was time to progression(TTP),...